Director, Commercial Accounting & FP&A

Who We Are

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.

Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic‑clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X‑NOVA clinical trial.

In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early‑stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN
1701 (targeting Nav
1.7) and XEN
1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

We are seeking a Director, Commercial Accounting and FP&A to join our team. This role will be a key member of the Finance department and will play a crucial role for revenue recognition and Gross to Net (GTN) accounting under ASC 606, while also serving as a strategic finance partner to the Commercial organization. The Director will establish scalable commercial accounting infrastructure, oversee pricing and top line analytics, support revenue guidance, and ensure SOX compliant controls as Xenon transitions from an R&D centric to a commercial centric company.

This role partners cross‑functionally to deliver accurate revenue reporting, robust forecasting, and clear executive‑level insights into business performance and value drivers. This role reports to the Senior Director, FP&A and is based out of Boston, MA, USA, in our Needham office. Hybrid positions require a minimum of two onsite days per week.

• Serve as the primary finance partner to the Commercial organization, providing financial leadership, guidance, and insight across pricing, payer mix, pipeline conversion, top line performance, and operating expenses
• Design, implement, and maintain GTN reserve methodologies, including documentation of reasonable assumptions: commercial and government rebates, chargebacks, copay and patient assistance programs, distribution service fees, returns and other variable consideration
• Responsible for monthly close processes for revenue, GTN, and operating expenses including journal entries, account reconciliations, true ups, and variance analysis
• Lead all financial reporting initiatives for the Commercial function, including accruals and monthly and quarterly reporting of financial results for management and department heads
• Manage the quarterly forecasting process by partnering with department managers to align the forecast with the most current business assumptions; ensure alignment between Commercial revenue forecast and guidance and report against such guidance, including analysis of pricing actions, margin dynamics, and market trends
• Manage government pricing reporting and ensure appropriate compliance…